Today we announced that patient dosing has commenced in the ONWARD Phase 3 clinical program evaluating ESK-001, an oral #TYK2 inhibitor, in moderate-to-severe Plaque #psoriasis. Topline data anticipated in 2026. Learn more: https://bit.ly/4c2rSvs
Congratulations, Jörn Drappa and the Alumis team! Exciting news on the Phase 3 trial. Best wishes for successful outcomes, new trials, and impactful partnerships! 🌟
Fantastic news Jorn and Alumis team!
Great work Jörn!
Congratulations Jörn Drappa
Founder, Member of Board & Strategic Advisor
1moWishing the entire clinical team all the very best !